39th Rostock Seminar for Cardiovascular Function and Hypertension, Rostock, Germany, July 3, 2010

摘要

Background: Nebivolol (NEB) is a (beta) 1-receptor blocker with nitric oxide-dependent vasodilating properties. NEB-induced nitric oxide release is mediated through the estrogen receptor. Method: Here, we tested the hypothesis that NEB decreases endo-thelial cell stiffness and that these effects can be abolished by both endo-thelial nitric oxide synthase and estrogen receptor blockade. Human endo-thelial cells (EAHy-926) were incubated with vehicle, NEB 0.7 nmol/l, metoprolol 200 nmol/1, 17(beta)-estradiol (E2) 15 nmol/l, the estrogen receptor antagonists tamoxifen 100 nmol/1 and ICI 182780 (ICI) 100 nmol/1, the nitric oxide synthase inhibitor N(omega)-nitro-L-arginine methyl ester 1 mmol/l and combinations of NEB and E2 with either tamoxifen, ICI or N(omega)-nitro-L-arginine methyl ester as well as metoprolol and ICI.